Both in vitro and in vivo studies have already been performed in human melanoma and indicate that COX-2 inhibitors can be a valuable adjunctive therapy for managing this tumor, contributing to the reduction of the proliferation and invasiveness of tumor cells and the inhibition of metastasis development [23,24,43,44]. Here, PTGS2 is linked to melanoma.